Everise | AI Transformation Index
Everise is a high-opportunity, low-durability business — the classic BPO trap in its most acute form. The massive cognitive labor pool of healthcare contac...

Overview
Everise is a healthcare-focused customer experience BPO that earns fee-for-service revenue by providing outsourced human agent labor — customer care, claims support, licensed sales, and omnichannel interaction management — primarily to Medicare Advantage payers, providers, and pharmacy benefits managers.
Executive Summary
Everise is a high-opportunity, low-durability business — the classic BPO trap in its most acute form. The massive cognitive labor pool of healthcare contact center agents represents genuine AI transformation potential, but the very same AI capability that makes Everise transformable also allows payers to bypass the BPO relationship entirely, migrating value toward AI-native CCaaS platforms and internal automation. For a PE investor, the strategic imperative is clear: accelerate AI transformation aggressively to defend margin and position Everise as an AI-orchestration layer rather than a labor arbitrage provider — but do so with eyes open to the structural ceiling, as the long-term demand for outsourced human agent volume will contract regardless of how well Everise executes.
Durability
How resilient is this business against AI disruption?
Market Substitutability
Profit Pool Migration
Barrier to Entry
Disintermediation Exposure
Switching Costs
Opportunity
How big a deal is AI for this business?
AI Applicability
Improvement Magnitude
Transformation Upside
Domain Intelligence Amplification
47.9
Ciridae AI Score
Durability Rationale
Everise's durability challenge is structural and fundamental: it is a human labor intermediary in a market where the thing it sells — trained agents conducting structured healthcare conversations — is precisely what AI voice and chat agents do cheaply and at scale. The regulatory complexity of Medicare Advantage and the emotional sensitivity of serving seniors provide a partial buffer, but these are friction factors, not moats, and payers have strong financial incentives to reduce outsourced headcount as AI alternatives mature. The most significant durability risk is disintermediation — large payers building internal AI contact center capability or procuring AI-native CCaaS platforms that eliminate the BPO relationship entirely, not just renegotiate it downward.
Opportunity Rationale
The AI opportunity for Everise is substantial and largely unrealized: with over 10,000 agents performing highly structured, conversational, rules-guided work, the cognitive labor compression potential is enormous — AI can dramatically reduce cost-per-interaction, increase agent throughput, automate quality monitoring, and enable new service tiers for previously uneconomic clients. The fact that Everise's engineering sophistication remains under 5% of headcount despite meaningful AI branding (EverAI Labs, Krisp partnership) signals that the step-change is still ahead of them, making this a legitimate target for AI transformation catalysis from PE sponsors or outside advisors.
Key Risks
Durability could prove worse than assessed if large Medicare Advantage payers (UnitedHealth, Humana, CVS/Aetna) accelerate internal AI contact center builds or standardize on AI-native CCaaS platforms (Genesys, Google CCAI) faster than contract cycles turn — eliminating the BPO relationship rather than renegotiating it, compressing revenue faster than Everise can pivot its business model.
Opportunity could prove lower than assessed if Everise's existing AI initiatives (EverAI Labs, Krisp partnership) are further along than the engineering headcount data suggests — meaning the unrealized step-change is smaller because transformation is already partially captured — or if healthcare payer clients resist AI deployment in senior-facing interactions due to CMS scrutiny or member experience concerns, slowing automation penetration.
Company Overview
| Headquarters | Plantation, Florida, United States |
| Products / Services | Healthcare solutions including patient-centered AI and healthcare-trained agents for end-to-end patient experience management, Pharmacy benefits management, Workforce management, Quality assurance, Systematic insights, Recruitment process outsourcing, Customer experience management across regulated industries, EverAI & Tech Solutions, Digital CX and Transformation, Managed Services |
| Deal Partners |
AI & Tech Initiatives
| Name | Description |
|---|---|
| EverAI Labs | An AI-driven initiative launched in partnership with GenAI industry experts. It aims to transform the entire customer experience agent journey by providing an integrated agent desktop suite embedded with a custom speech AI stack tailored for customer management centers. The platform maps all internal agent processes with every customer interaction, offering a single end-to-end workflow from hiring through employment. The technology empowers agents with real-time insights and automation to improve productivity and customer satisfaction. |
| Strategic Partnership with Krisp | Everise formed a strategic partnership with Krisp to deploy Krisp's real-time voice AI platform across its global workforce of 10,000+ agents. This AI-powered platform enhances customer experience by providing real-time voice interaction improvements such as accent neutralization, noise cancellation, speech interpretation, and agent assist features. |
| Everact | The first agentic AI platform for conversational retail intelligence. |
PE / Ownership History
| Event | Details |
|---|---|
Warburg Pincus invested in Everise, partnering with Brookfield. October 2023 | This investment valued Everise at around $1 billion. The investment was to accelerate Everise's growth through business expansion and M&A. |
Brookfield Asset Management acquired a majority stake in Everise. December 2020 | The acquisition was valued at approximately $450 million. Everstone Group was the seller. |
Everstone Group divested Everise to Brookfield Business Partners. December 2020 | The divestiture price was approximately $450 million. |
Everstone Group invested in Everise. 2016 | Everstone Group initially controlled Everise, which was founded in partnership with Sudhir Agarwal's Sunrise BPO. Everstone acquired C3, a US-based BPO company, in December 2016, which evolved into Everise. The divestiture price was approximately $450 million. |
Executives
| Name | Background |
|---|---|
Sudhir Agarwal CEO | Veteran leader known for building global teams with precision and transforming challenges into opportunities through strategic vision and a human-centered approach. Previously, Founder and CEO at C3/CustomerContactChannels. |
Steven Amaya CFO | Over 15 years of experience in finance and accounting. Previously CFO at Carenet Health and held senior finance roles at TaskUs. |
Yogesh Khattar COO | COO at Everise for about 1 year and 7 months. His previous roles include Head of US Operations at TELUS Health and Chief Operating Officer at Customer Contact Channels/C3. |
Sheena Ponnappan Chief People Officer (CPO) | Oversees HR strategy, talent engagement, compensation, staffing, succession planning, and leadership development. Has over 20 years of experience in HR across diverse industries and countries. Previously worked at Aegis. |
Robert Jimenez Chief Revenue Officer (CRO) | Leads revenue generation and business growth strategies. Veteran leader with strategic vision. |
Maneesh Garg Chief of Staff and Deputy Chief Financial Officer | Supports financial leadership and strategic initiatives. Veteran leader. |
Ganapathy Subramaniyan Chief Information Officer (CIO) | Oversees technology strategy and IT operations. Veteran leader. |
Heather Hague Vice President | Vice President at Everise for about 9 months. |
Paul Shamansky Senior Vice President Operations | Senior VP Operations at Everise for nearly 6 years. Previously worked at TTEC and Optum. |
Nishit Nandwana VP Operations | VP Operations focusing on Contact Center & Customer Experience, P&L, and Digital Transformation. Previously held senior operations roles at Globee GBS and STARTEK. |
Brookfield Asset Management